Adult CAD treatment helps 2 children with resistant disease
Researchers call for clinical trials evaluating Enjaymo in kids
Written by |
Researchers say Enjaymo, approved for adults with CAD, may be safe and effective in children. (Photo by iStock)
Enjaymo (sutimlimab-jome), an infusion therapy approved for adults with cold agglutinin disease (CAD), was safe and effective in two children with severe, treatment-resistant CAD, a study showed.
“To our knowledge, these are the first reported uses of [Enjaymo] in the pediatric population,” wrote the researchers, who called for appropriately controlled clinical trials to evaluate Enjaymo in children with CAD.
The study, “Successful Use of Sutimlimab in two Pediatric Patients With Refractory Cold Antibody-Mediated Autoimmune Hemolytic Anemia,” was published in Pediatric Blood & Cancer.
CAD is caused when self-reactive antibodies known as cold agglutinins mistakenly attack red blood cells at cold temperatures, marking them for destruction (hemolysis). The complement cascade, part of the immune system, mediates this destruction, leading to a shortage of red blood cells (anemia) and other CAD symptoms.
For kids, risk is rare but potentially serious
The risk for CAD typically increases after age 55, yet some children develop the disorder. In these cases, CAD usually develops secondary to an infection and lasts a relatively short time. Still, more than half of pediatric CAD patients develop severe anemia requiring blood transfusions.
“Relapse is rare and is typically associated with underlying immune dysregulation that may result in refractory [treatment-resistant] disease warranting aggressive therapies to control episodes,” the researchers wrote.
Enjaymo is an antibody-based therapy designed to block C1s, a protein in the complement pathway. Administered via an intravenous (into-the-vein) infusion, it’s approved to reduce hemolysis in adults with CAD. However, it hasn’t been studied or approved in children with the disorder.
A team led by researchers at Children’s Hospital Los Angeles described how they used Enjaymo to treat two children with refractory CAD.
The first was a 4-year-old girl who developed CAD at age 2. She carried a known mutation in the DIAPH1 gene, which is known to cause a neurodevelopmental disorder, and had a history of immune thrombocytopenia, an autoimmune condition that destroys platelets (blood fragments involved in clotting).
She arrived at the center with yellowing of the skin and eyes, pallor, a runny nose, and reduced oral intake. Blood tests showed severe anemia, high levels of hemolysis markers, and low platelet counts.
She tested positive on a Coombs test, which detects red blood cells bound to antibodies and/or complement proteins, and had high levels of cold agglutinins, both signs of CAD. Tests for viruses were negative.
She first received a warmed blood transfusion, with little effect, then plasma exchange, a procedure that removes antibodies from blood. Corticosteroids and mycophenolate mofetil, two immunosuppressive treatments, were also administered. Despite treatment and warming protocols, severe hemolysis persisted, and the girl required daily blood transfusions.
Blood levels of two complement proteins (C3 and C4) were lower than normal, indicating complement activation. Given the ongoing hemolysis and lack of response to standard therapies, Enjaymo was started at a weight-based dose derived from adult prescribing information.
The girl’s hemolysis markers began to fall, alongside her need for transfusions. Complement protein levels eventually normalized and remained in the normal range. She also received antibiotics to prevent infection.
She needed no further transfusions after a second dose of Enjaymo and was soon discharged. In total, she received six doses, and the therapy was stopped after hemolysis markers normalized. She was also weaned from corticosteroids, and has had no recurrence for three years. No treatment-related adverse events were reported.
The second child was a 12-month-old boy who had liver failure at birth due to immune-mediated liver disease and who underwent a liver transplant. He was seen about a year later with low physical activity and vomiting.
Blood tests revealed severe anemia, hemolysis, low C3 and C4, with a positive Coombs test. He also tested positive for cytomegalovirus infection and received appropriate antiviral treatment.
His condition was complicated by acute kidney injury requiring continuous kidney-replacement treatment, as well as dangerously high blood pressure and low platelet counts.
He received warmed blood transfusions, corticosteroids, and rituximab, a therapy that depletes antibody-producing immune B-cells and is commonly used off label in CAD.
Because of uncontrolled hemolysis and liver failure, Enjaymo was started at a weight-based dose. Within days, blood tests showed no signs of anemia or hemolysis, and his C3 and C4 levels normalized before discharge.
Enjaymo “was continued for a total of seven doses and stopped upon normalization of … hemolytic markers,” the researchers wrote.
The boy remained on antiviral treatment and antibiotics. At the time of the report, he had been off Enjaymo for over two months, with stable red blood cell counts.
“Despite the success of these cases, it is important that proper clinical trials of [Enjaymo] be conducted in children to demonstrate safety, efficacy, and discontinuation criteria in severe cases of [CAD],” the team wrote.
Leave a comment
Fill in the required fields to post. Your email address will not be published.